Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02 2021 - 4:05PM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, today announced that it
has granted inducement stock options to purchase an aggregate of
144,580 shares of its common stock to eighteen new employees. These
inducement stock options have a grant date of May 31, 2021, and
were granted as inducements material to the new employees entering
into employment with Biocept in accordance with Nasdaq Listing Rule
5635(c)(4).
The inducement stock options have an exercise price of $4.52 per
share, the closing price of Biocept’s common stock on May 28, 2021
(which is the last date preceding the grant date on which the
closing price of Biocept’s common stock was reported), are
non-qualified stock options, have a ten-year term and vest over
four years, with 25% of the shares vesting on the one-year
anniversary of the vesting commencement date and the remaining 75%
of the shares vesting in equal monthly installments over the
following 36 months, subject to the new employee’s continued
service with Biocept through the applicable vesting dates. The
inducement stock options are subject to the terms and conditions of
Biocept’s Amended and Restated 2013 Equity Incentive Plan.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid (CSF) assay that detects cancer that has
metastasized to the central nervous system. Biocept’s patented
Target Selector™ technology captures and quantitatively analyzes
CSF tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210602005390/en/
Investor Contact: Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
Media Contact: Sampson PR Group Andrea Sampson
asampson@sampsonprgroup.com, (562) 304-0301
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024